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ABSTRACT 
A good model of neuronal death that reproduces the characteristic tau (τ) 
hyperphosphorylation of Alzheimer´s disease is the use of okadaic acid (OA). The aim of this 
study was to determine the contribution of α7 and β2* nicotinic acetylcholine receptor 
(nAChR) subtypes to neuroprotection against OA in the SH-SY5Y cell line, by using the 
selective α7 and β2* nAChR agonists PNU 282987 and 5Iodo-A85380, respectively. The 
results of this study show that both α7 and β2* nAChR can afford neuroprotection against 
OA-induced neurotoxicity. Protection mediated by α7 nAChRs was independent of Ca2+ and 
involved the intracellular signaling pathway JAK2/PI3K/Akt. When Ca2+ entry was promoted 
through the α7 nAChR by using the α7-selective positive allosteric modulator PNU 120596, 
protection was lost. By contrast, protection mediated by β2* nAChRs was Ca2+-dependent 
and implicated the signaling pathways PI3K/Akt and ERK1/2. Both α7 and β2* nAChR 
activation converged on down-regulation of GSK3β and reduction of τ phosphorylation in 
cells undergoing cell death induced by OA. Therefore, targeting nAChR could offer a strategy 
for reducing neurodegeneration secondary to hyperphosphorylation of protein τ. 
 
 
Key words: Okadaic acid, SH-SY5Y neuroblastoma, nicotinic receptors, 
hyperphosphorylation of Tau, PNU 282987, 5IA 85380. 
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INTRODUCTION 
Alzheimer Disease (AD) is characterized by a progressive loss of memory, often with 
deterioration of language as well as deficits in visual and motor coordination. At the cellular 
level, it has been shown that cell death (Cummings 2004) occurs especially in cholinergic 
neurons (Whitehouse et al. 1982) and that this neuronal death is related to the loss of memory 
in AD patients (Haass and Selkoe 2007). At the molecular level, AD is characterized by the 
presence of tangles rich in the intracellular microtubule-associated protein tau (τ) (Lee and 
Trojanowski 1992) and extracellular deposits of amyloid peptides that form senile plaques 
(Price et al. 1991). A link between these two proteins has been demonstrated since beta-
amyloid can trigger tau phosphorylation and the subsequent degeneration of the affected 
neurons (Busciglio et al. 1995; Alvarez et al., 2002; Liu et al., 2004). It has also been shown 
that beta-amyloid fibrils can induce neurotoxicity and tau hyperphosphorylation without 
plaque formation; it therefore seems that beta-amyloid pathology could precede 
hyperphophorylation of tau and the formation of neurofibrillary tangles and 
neurodegeneration (Busciglio et al., 1995) 
In this study we have focused on  τ hyperphosphorylation as a mechanism for neuronal 
death (Irizarry et al. 1997; Pizzi et al. 1995). In the brains of AD patients, there is a high 
percentage of hyperphosphorylated τ protein (Avila 2000) and an accumulation, in certain 
neurons, of paired helical filaments (PHF) in which hyperphosphorylated τ is the major 
protein present (Grundke-Iqbal et al. 1986; Grundke-Iqbal et al. 1988). Destabilization of 
microtubules and the consequent decrease in axonal transport is believed to be responsible for 
retrograde degeneration of neurons in AD (Alonso et al. 1994; Alonso et al. 1997; De Vos et 
al. 2008) and also for cell death in “in vitro” models of τ hyperphosphorylation (Cowan et 
al.; Perez et al. 2002; Tanaka et al. 1998). Inhibition of phosphatases that act on some 
abnormally phosphorylated sites characteristic of AD (Gong et al. 1994) may also lead to τ 
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 4 
protein hyperphosphorylation (Tanaka et al. 1998). These phosphatases include the Ser/Thr 
PP-1, PP-2A and PP-2B (Gong et al. 1994; Wang et al. 1995) and their  activity has been 
shown to be diminished in brain tissue from Alzheimer´s  disease patients (Gong et al. 1995; 
Gong et al. 1993).  
Okadaic acid, a seaweed toxin, inhibits phosphatases with the preference PP2A > PP1 
> PP2B. A consequence of its action is τ hyperphosphorylation “in vivo” (Tian et al. 2004) 
and “in vitro” (Tanaka et al. 1998; Uberti et al. 1997). It therefore provides a good model that 
reproduces τ hyperphosphorylation and cell death. In this study we have used OA in the 
human neuroblastoma cell line SH-SY5Y to model aspects of cell damage relevant to 
Alzheimer’s disease (Arias et al. 2005; Cowan et al.; Perez et al. 2002; Tanaka et al. 1998), in 
order to investigate neuroprotective strategies. 
There is a body of evidence for nAChRs exerting neuroprotective effects against a 
variety of insults (Dajas-Bailador and Wonnacott 2004; Picciotto and Zoli 2008). With 
respect to Alzheimer’s disease, nicotinic agonists have been reported to be effective against 
Aβ-induced toxicity “in vivo” and “in vitro” (Arias et al. 2005; Kihara et al. 1998). Their 
efficacy in τ hyperphosphorylation models is less well documented. 
The majority of studies have highlighted the α7 nAChR as the main nAChR subtype 
responsible for neuroprotective effects mediated by nicotinic agonists (Arias et al. 2005; 
Bitner et al. 2009; Haydar and Dunlop). However, non α7 nAChR subtypes have also been 
found to contribute to neuroprotection (Tizabi et al. 2004), depending on the cell type and 
toxic stimulus. Because the roles of different nAChR subtypes are not fully understood, we 
have exploited subtype-selective ligands, namely the α7 nAChR agonist PNU 282987 
(Bodnar et al. 2005), the β*-selective agonist 5-Iodo-A-85380 (5IA 85380) (Mukhin et al. 
2000) and the α7 nAChR positive allosteric modulator PNU 120596 (Hurst et al. 2005) in this 
study  
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The results demonstrated nAChR-mediated neuroprotection against OA. Protection 
mediated by α7 nAChRs was independent of Ca2+ and involved the intracellular signaling 
pathway JAK2/PI3K/Akt. Sustained activation of α7 nAChR to promote Ca2+ entry was 
achieved with the positive allosteric modulator but under these conditions protection was lost. 
In contrast, protection mediated by β2* nAChRs was Ca2+-dependent and implicated the 
signaling pathways PI3K/Akt and ERK1/2. Both α7 and β2* nAChR activation converged on 
the inhibition of GSK-3β, and consequently τ phosphorylation, to afford neuroprotection. 
 
MATERIALS AND METHODS 
 
Materials 
PNU 282987, 5IA 85380, PNU 120596, AG 490, LY 294002, PD 98059 were 
purchased from Tocris Cookson Inc. (Bristol, UK). Okadaic acid, α-bungarotoxin (BGT), 
dihydro-β-erythroidine (DHβE), methyllycaconitine (MLA), mecamylamine and AR-A01448 
were purchased from Sigma-Aldrich (St. Louis, MO). α-conotoxin-MII and α-conotoxin-
AuIB were synthesized as previously described  (Luo et al., 1998). Alpha-conotoxin AuIB 
selectively blocks α3β4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine 
release (Lou et al, 1998). 
 
Culture of SH-SY5Y Cells 
SH-SY5Y cells were maintained in a 1:1 mixture of F-12 Nutrient Mixture (Ham12) 
(Sigma Aldrich, Madrid, Spain) and Eagle’s minimum essential medium (EMEM) 
supplemented with 15 non-essential amino acids, 1 mM sodium pyruvate, 10% heat-
inactivated fetal bovine serum (FBS), 100 units/ml penicillin, and 100 µg/ml streptomycin 
(reagents from Invitrogen, Madrid, Spain). Cultures were seeded into flasks containing 
supplemented medium and maintained at 37°C in a humidified atmosphere of 5% CO2 and 
Page 5 of 40 Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 6 
95% air. For assays, SH-SY5Y cells were sub-cultured in 48-well plates at a seeding density 
of 1 x 105 cells per well. Cells were treated with the drugs before confluence in F-12/EMEM 
with 1% FBS. These cells, when undifferentiated, express functional nicotinic receptors 
(Dajas-Bailador et al. 2002a). All cells used in this study were used at a low passage number 
(<13). 
 
Measurement of lactate dehydrogenase activity  
Extracellular and intracellular lactate dehydrogenase (LDH) activity was measured 
spectrophotometrically using a cytotoxicity cell death kit (Roche Diagnostics, Mannheim, 
Germany) according to the manufacturer's instructions. Total LDH activity was defined as the 
sum of intracellular and extracellular LDH activity; released LDH was defined as the 
percentage of extracellular compared with total LDH activity. 
 
Calcium fluorimetry.  
Increases in intracellular Ca2+ in confluent cultures of SH-SY5Y cells grown in 96-
well plates were monitored as described by Dajas-Bailador et al. (2002a). In brief, SH-SY5Y 
cells were washed twice with Tyrode’s salt solution (TSS: in mM 137 NaCl, 2.7 KCl, 1.0 
MgCl2, 2.5 CaCl2, 0.2 NaH2PO4, 12 NaHCO3, 5.5 glucose; pH 7.4) and incubated with the 
membrane-permeable Ca2+-sensitive dye fluo-3 AM (10 µM) and 0.02% pluronic F127 for 1 h 
at room temperature in the dark. Cells were then washed twice with TSS, before adding 80 µL 
buffer, with or without nAChR antagonists or PNU 120596, per well. After 10 min, basal 
fluorescence (excitation 485 nm, emission 520 nm) was recorded for 4 s using a Fluoroskan 
Ascent fluorescence plate reader (Labsystems, Helsinki, Finland). nAChR agonists (20 µL) 
were added using an automatic dispenser and changes in fluorescence were monitored for a 
further 10 s. To normalize fluo-3 AM signals, responses from each well were calibrated by 
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 7 
determination of the maximum and minimum fluorescence values by addition of 0.2% Triton-
X100 (Fmax) followed by 40 mM MnCl2 (Fmin). Maximum fluorescence responses were 
calculated as a percentage of Fmax - Fmin.  
 
Immunoblotting 
SH-SY5Y cells were washed once with cold phosphate-buffered saline and lysed in 
100 µL ice-cold lysis buffer (1% Nonidet P-40, 10% glycerol, 137 mmol/L NaCl, 20 mmol/L 
Tris-HCl, pH 7.5, 1 µg/mL leupeptin, 1mmol/L phenylmethylsulfonyl fluoride, 20 mmol/L 
NaF, 1 mmol/L sodium pyrophosphate, and 1 mmol/L Na3VO4). Protein (30 µg) from the cell 
lysates was resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) and transferred to PVDF membranes (Amersham). Membranes were incubated with 
the following antibodies: anti-extracellular regulated kinase 1/2 (ERK 1/2) and anti-phospho-
ERK1/2 at 1:1000 (Santa Cruz Biotechnology Inc., Heidelberg, Germany); anti-JAK-2 , anti-
phospho-Tyr-211-JAK-2, Anti-phospho-Thr-308-Akt, Anti-Akt, Anti-phospho-Ser-9-GSK3-
β, Anti-phospho-Tyr-216-GSK3-β and Anti-GSK-3β at 1:1000 (Cell Signalling, Izasa S.A., 
Barcelona, Spain); anti-β-actin at 1:100000 (Sigma, Madrid, Spain). Membranes were also 
incubated with Anti-phospho-Ser-396/404-Tau and Anti-Tau at 1:1000 which were 
previously used by Lucas et al. (2001). Appropriate peroxidase-conjugated secondary 
antibodies at 1:10000 were used to detect proteins by enhanced chemiluminescence. 
 
Cytoskeleton staining 
SH-SY5Y cells were plated on coverslips: 24-48 h after plating the cells, they were 
separated into 4 groups: two were treated with EMEM, one with 10 µM PNU282987 and 
another one with 100 µM 5IA 85380 for 24 h. Then, the control group was maintained in 
EMEM  and the rest of the groups were treated with okadaic acid for 5 h. After exposure of 
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 8 
the cells to the different treatments, they were rinsed three times with PBS (NaC1 9g/L, 
NaH2PO4 10 mM, K2HPO4 10 mM). Then, they were fixed in 2% paraformaldehyde in PBS 
for 15 min and washed three more times with PBS.  Cells were permeabilized by exposure to 
0.1% triton in PBS for 1 min. Preparations were washed several times with PBS and then 
incubated at room temperature with rhodamine-labeled phalloidin (Sigma-Aldrich, Madrid, 
Spain) 1:1000 in PBS. Coverslips were then thoroughly washed with PBS. In the second 
rinsing, Hoechst (Invitrogen, Madrid, Spain) was added (1 µL/mL) in order to mark nuclei 
and after the third rinsing the coverslips were mounted in glycerol-PBS (1:1 ; vol/vol). Images 
were taken with a confocal microscope (TCS SPE; Leica, Wetzlar, Germany). 
 
Statistical Analysis  
Statistically significant differences between groups were determined by an analysis of 
variance followed by a Newman-Keuls post hoc analysis. The level of statistical significance 
was taken at p < 0.05. 
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RESULTS 
 
Effect of different nicotinic agonists and the α7 allosteric modulator PNU 120596 on OA-
induced toxicity 
Exposure of SH-SY5Y cells to 30 nM OA for 16 h increased LDH release from 7-10 
% (basal conditions) to 36-42 % (OA treatment), consistent with the induction of modest 
levels of cell death (Fig 1). To determine if nAChRs are able to protect against OA-induced 
toxicity we incubated SH-SY5Y cells with either the α7 or β2* selective agonist PNU 282987 
(Parada et al.) or 5IA 85380, respectively, or with the α7 allosteric modulator PNU 120596. 
With pre-incubation increasing concentrations of PNU 282987, for 24 h before the addition of 
OA (see protocol at the top of fig. 1), we observed a gradual reduction in cell death measured 
as LDH released into the extracellular medium. PNU 282987 exerted a significant but partial 
protection against OA-induced toxicity at 10 and 30 µM (fig. 1 A). 5IA 85380 also produced 
significant protection at 100 µM (fig. 1 B). The α7 positive allosteric modulator PNU 120596 
alone showed no protection at any of the concentration assayed (0.3 to 10 µM) (fig. 1 C) 
 
Intracellular Ca2+ increases mediated by PNU 282987, 5IA 85380 and PNU 120596 plus 
PNU 282987. 
SH-SY5Y cells express α3, α5, α7, β2, and β4 nAChR subunits (Gentry and Lukas 
2002; Peng et al. 1994). In order to determine the effects of PNU 282987 and 5IA 85380 on 
intracellular Ca2+ levels and their selectivity on nAChR subtypes, we measured Ca2+ signals 
in SH-SY5Y cells loaded with the dye Fluo-3. For these experiments we employed 
concentrations of the agonists that showed protection in the previous section in order to gather 
information about the possible neuroprotective mechanisms of action. 
PNU 282987 alone did not induce a significant increase in [Ca2+]c at the 
neuroprotective concentration of 10 µM. However, when the agonist was added to cells pre-
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incubated with the allosteric modulator PNU 120596, a significant increase in fluorescence 
was observed, consistent with increased cytosolic Ca2+. These [Ca2+]c increases were 
mediated by activation of nAChR since the signal was significantly attenuated by the non-
selective nAChR antagonist mecamylamine. In particular, these Ca2+ signals could be 
attributed to stimulation of the α7 subtype nAChR since the selective α7 nAChR antagonists 
αBGT and MLA completely inhibited the increases in fluorescence (fig. 2 A).  
5IA 85380, at the protective concentration of 100 µM, produced a significant 
intracellular Ca2+ signal by itself (fig. 2B). Selective β2* antagonists such as DHβE and α-
conotoxin MII or mecamylamine were able to significantly block Ca2+ signals induced by 5IA 
85380. However, α3β4 (α-conotoxin AuIB) or α7 (BGT) antagonists did not modify the 
[Ca2+]c responses mediated by 5IA 85380.  
Therefore, under these experimental conditions, 5IA 85380 appears to be activating 
heteromeric β2-containing nAChRs while PNU 282987 is activating α7 nAChRs. 
 
Ca2+-dependence in the protective effects of 5IA 85380 and PNU 282987  
To determine the influence of Ca2+ entry mediated by α7 and β2* nAChRs in the 
neuroprotective effects afforded by PNU 282987 and 5IA 85380, we performed experiments 
in the absence or presence of extracellular Ca2+. Since prolonged lack of extracellular Ca2+ 
can be a toxic stimulus per se, we first performed a time course to determine the minimum 
time of agonist pre-incubation required to achieve the maximal protective effect (see protocol 
on top of Fig. 3). 
As figure 3 illustrates, PNU 282987 reduced LDH release in cells injured with OA in a 
time-dependent manner; cell death was significantly reduced following only 5 min incubation 
with the agonist, 24 hours before exposing the cells to 16 h to OA (fig. 3 A). In the case of 
5IA 85380, protection was significant following 1 h pre-incubation (fig. 3 B). For 
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comparability we selected a 4 h preincubation period for both agonists since this length of 
exposure produced a level of protection similar to that seen following 24 h pre-incubation. 
The presence or absence of extracellular Ca2+ was maintained only during the 4 h exposure to 
the nicotinic agonist; thereafter, the medium was replaced with fresh EMEM containing Ca2+ 
for 20 h, and OA was then added for 16 h. The results show that protection mediated by 5IA 
85380 was dependent on extracellular Ca2+ (fig. 3 D) while that induced by PNU 282987 was 
not (fig. 3 C). Moreover, when cells were pre- and co-incubated with the α7 allosteric 
modulator PNU 120596 in the presence of Ca2+, the neuroprotective effect of PNU 282987 
was lost (fig. 3C). Finally, in the absence of extracellular Ca2+, PNU 120596 did not reverse 
the neuroprotection mediated by PNU 282987 (fig. 3 C). These results suggest that Ca2+ entry 
via β2* nAChR activation is required to afford a neuroprotective effect. However, in the case 
of the α7 nAChR, PNU 282987 exerted a Ca2+-independent neuroprotective effect. 
Furthermore, as shown by the experiments with the α7 agonist in the presence of the α7 
nAChR allosteric modulator that promotes Ca2+ entry though the α7 nAChR subtype (Fig. 
2A), protection was lost in a Ca2+ dependent way (Fig. 3 C). 
 
JAK-2 is involved in protection mediated by α7 but not by β2* nAChRs 
JAK-2 is a protein that can be physically associated with α7 nAChRs and activated 
when nicotine binds to this receptor subtype (Shaw et al. 2002). To determine if α7 and/or 
β2* nAChR subtype stimulation could activate this kinase under our experimental conditions, 
SH-SY5Y cells were incubated with PNU 282987 10 µM, PNU 282987 10 µM plus PNU 
120596 10 µM or 5IA 85380 100 µM for different times (5, 15, 30 min and 1 or 24 h) and 
JAK-2 phosphorylation was then analyzed by western blotting. Cells treated with PNU 
282987 10 µM showed maximally phosphorylated JAK-2 after 15 min incubation; thereafter, 
phospho-JAK 2 decreased to basal levels (fig. 4 A). In contrast, 5IA 85380 failed to promote 
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the activation of JAK-2 at any of the times tested (fig. 4 B). Also, no alteration in phospho-
JAK-2 levels was observed when the α7 agonist was incubated in the presence of the α7 
allosteric modulator (fig. 4 C). 
JAK-2 has been previously shown to be involved in neuroprotection induced by 
nicotine via α7 nAChR stimulation in neurons injured with Aβ1-42 (Shaw et al. 2002). For this 
reason, and because the α7-selective agonist increased JAK-2 phosphorylation, we evaluated 
if the protective effect of PNU 282987 against OA would be lost in the presence of a JAK-2 
inhibitor, AG-490. To corroborate that JAK-2 activation was linked with its action on the α7 
and not with the β2* nAChRs, we also included 5IA 85380 in these experiments. As shown in 
figure 4 D, the protective effect of PNU 282987 was completely prevented by pre- (15 
minutes before) and co-incubation with AG-490, but this compound did not affect protection 
afforded by 5IA 85380. Therefore, these results indicate that JAK-2 is linked to α7 nAChR-
mediated survival. Moreover, the presence of the α7 allosteric modulator prevented PNU 
282987-induced JAK phosphorylation (fig. 4 C), and this result correlates with the loss of 
protection under the same drug treatment conditions (see Fig.1C).  
 
Implication of PI3K/Akt in the neuroprotective effect mediated by α7 and β2* nAChR 
stimulation 
Multiple nicotinic agonists cause activation of PI3K/Akt (Kihara et al. 2001). 
PI3K/Akt is known to be one of the targets of JAK-2 (Shaw et al. 2002). To investigate if 
exposure to α7 and β2* nAChR agonists led to Akt activation, we measured Akt 
phosphorylation by western blot analysis. Incubation with PNU 282987 or 5IA 85380 
produced a statistically significant activation of Akt at 5 and 15 minutes for both agonists (fig. 
5 A and B). To determine if protection afforded by α7 and β2* nAChR was dependent on the 
PI3K/Akt pathway, cells were pre-(15 minutes before) and co-incubated with a PI3K 
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inhibitor, LY 294002 (3 µM). Protection elicited by PNU 282987 and 5IA 85380 against OA-
toxicity was prevented by the inhibitor LY 294002 (fig. 5 C). Taken together, these results 
indicate that protection obtained with both nicotinic agonists is dependent on activation of 
PI3K/Akt.  
 
ERK 1/2 is involved in the neuroprotective effect mediated by 5IA 85380 but not by PNU 
282987. 
The MAPK intracellular pathway has also been implicated in neuroprotection 
processes mediated by nAChR activation (Egea et al. 2007). To assess if PNU 282987 and/or 
5IA 85380 were able to activate ERK 1/2, we measured the phosphorylation of these kinases 
by western blot. As shown in figure 6 A, PNU 282987 10 µM by itself did not produce ERK 
1/2 phosphorylation at any of the time intervals studied. However, 5IA 85380 significantly 
increased the level of P-ERK 1/2 after 15 min (fig. 6 B). To corroborate the involvement of 
MAPK activation in the neuroprotective effect mediated by 5IA 85380 and not by PNU 
282987, we employed a MEK inhibitor, PD 98059. As shown in figure 6 C, the presence of 
PD 98059 completely inhibited the protection induced by 5IA 85380 but had no effect on that 
of PNU 282987. From these results, it can be concluded that MEK participates in the 
neuroprotective effect mediated by β2* but not by α7 nAChR stimulation. 
 
Involvement of GSK-3β in neuroprotection induced by α7 and β2* nAChR. 
GSK-3β is a substrate of Akt. Akt phosphorylates GSK-3β at position Ser-9 and this 
phosphorylation inactivates GSK-3β (Stambolic and Woodgett 1994). On the other hand, 
phosphorylation at Tyr-216 has the opposite effect and activates GSK-3β; however the 
kinase(s) responsible for this phosphorylation are not well characterized (Cole et al. 2004; 
Hughes et al. 1993; Wang et al. 1994). We therefore measured nAChR agonist-induced GSK-
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3β phosphorylation by western blot. As shown in figure 7, both PNU 282987 and 5IA 85380 
were able to increase Ser 9 phosphorylation after 15 and 5 minutes incubation, respectively 
(fig. 7 A and B). Subsequently, this phosphorylation decreased over time and after 24 hours it 
was not statistically significantly different from OA control. P-Tyr 216-GSK-3β and total 
GSK-3β levels were not altered at any of the incubation times (data not shown).  
To determinate if GSK-3β inhibition could be involved in the protection mediated by 
PNU 282987 and 5IA 85380, we conducted a neuroprotection experiment in the presence or 
absence of a GSK-3β inhibitor, AR-A014418. Figure 7 C shows how AR-A014418 alone 
produced protection against OA and such protection was not statistically different from that 
obtained with the nicotinic agonists alone. Since the combination of nAChR agonists plus 
AR-A014418 did not afford a greater neuroprotective effect, we deduce that both agonists 
were acting through a common mechanism which involves a transient inactivation of GSK-
3β. 
To further investigate how nicotinic agonists and the GSK-3β inhibitor, pre-incubated 
for 24 h before adding OA, induced neuroprotection we evaluated the activation and the 
expression of GSK-3β at the end of the experiment, i.e. after OA treatment. Western blot 
analysis of GSK-3β was carried out after OA exposure for 16 hours alone or in the presence 
of the neuroprotective compounds. As shown in figure 8 A, the expression of total GSK-3β 
increased after OA treatment and nicotinic agonists prevented this increased expression to 
almost basal levels (fig. 8 A); a similar effect was obtained with the GSK-3β antagonist AR-
A014418. Interestingly, OA produced a significant increase of total P-Tyr 216 that was also 
significantly reduced by the nicotinic agonists and AR-A014418 (fig. 8 B).  
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α7 and β2* nicotinic agonists reduced τ hyperphosphorylation 
As previously mentioned, OA is an inhibitor of phosphatases that augments τ 
hyperphosphorylation. In addition, one of the kinases involved in τ phosphorylation is GSK-
3β, whose target in the τ substrate is Ser396/404 (Cho and Johnson 2004). The question of 
how GSK-3β activity affected the phosphorylation on τ Ser396/404 residue was raised. After 
OA treatment for 16 h in the presence or absence of PNU 282987, 5IA85380 and AR-
A014418, we measured Ser-396/404 τ phosphorylation by western blot. As shown in figure 9, 
PNU 282987, 5IA 85380 and AR-A014418 significantly reduced τ phosphorylation induced 
by OA on its Ser396/404 residue. 
 
Effect of α7 and β2* nicotinic agonists on the cytoskeleton alterations caused by okadaic 
acid 
AO, besides causing hyperphosphorylation of tau, induces changes in the cytoskeleton 
that are identified with strong retraction and rounding in cell morphology (Vale and Botana, 
2008; Yoon et al., 2008; Cabado et al., 2004). Therefore, we also analyzed how treatment of 
the cells with nicotinic agonists could modify the changes in the cytoskeleton induced by OA 
treatment. 
As shown in figure 10, control cells exposed only to EMEM (Fig. 10A) showed a 
fibrous cytoarchitecture with a well extended and branched morphology. OA-treated cells 
showed a retracted morphology with almost no neurites (Fig. 10B). When cells were pre-
incubated for 24 h with PNU282987 (10 µM) (Fig. 10C) or 5IA 85380 (100 µM) (Fig. 10D) 
before adding OA, we observed a partial recovery of the fibrous and branched 
cytoarchitecture as observed in intact cells. This partial recovery of the cytoarchitecture 
correlates with the partial neuroprotective effects observed when measured as LDH release 
(Fig. 1 A and B). 
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DISCUSSION 
 
Central to this study is the observation that both α7 and β2* nAChR can transduce 
signals through different mechanisms to provide protection of cells that undergo 
hyperphosphorylation of τ. Ultimately, these distinct signalling pathways converge on the 
regulation of GSK3β and reduction of τ phosphorylation. 
To analyse how Ca2+ could be involved in the protective effects of PNU 282987 and 
5IA 85380, we first measured cytosolic Ca2+ levels in Fluo-3-loaded SH-SY5Y cells. 
Interestingly, PNU 282987 at the protective concentration of 10 µM did not induce a 
measureable intracellular Ca2+ increase, but in the presence of the allosteric modulator PNU 
120596, it gave a robust intracellular Ca2+ rise which was blocked by the α7 nAChR-selective 
antagonists BGT and MLA. These results are in agreement with those previously reported in 
bovine chromaffin cells (del Barrio et al.) or PC12 cells (Dickinson et al. 2007). Unlike PNU 
282987, 5IA 85380 alone, at a protective concentration, was able to increase intracellular Ca2+ 
levels; this response was blocked by selective β2* antagonists such as DHβE and α-conotoxin 
MII but not by α7 (Dickinson et al. 2007) or α3β4 selective antagonists, which corroborates 
the selectivity of 5IA 85380 for β2* nAChR subtype (Dajas-Bailador et al. 2002a; Mukhin et 
al. 2000).  
The observation that the α7 agonist exerted its protective effect without apparently 
inducing intracellular Ca2+ increases is against the belief that Ca2+ is the second messenger 
responsible for kinases intracellular activation involved in neuroprotection mediated by α7 
nAChR (Dajas-Bailador et al. 2002b; Donnelly-Roberts et al. 1996; Ferchmin et al. 2003). 
However, examination of the protective efficacy of PNU 282987 in a medium without Ca2+ 
corroborated the Ca2+-independence of the protective effect. In fact, when Ca2+ was forced to 
increase via α7 nAChR activation, with the aid of the positive allosteric modulator, protection 
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was lost in a Ca2+ dependent way. In contrast, the protective effect of 5IA 85380 was 
dependent on extracellular Ca2+ which corroborates a previous study in which this agonist 
offered Ca2+-dependent neuroprotection against glutamate-induced toxicity (Ueda et al. 
2008). Taken together, these results indicate that α7 nAChR protection is Ca2+-independent 
while β2* nAChR protection is Ca2+-dependent. 
Regarding the intracellular signalling pathways involved in the neuroprotective 
mechanism associated with the nAChR activation, there are several intracellular kinases 
involved in this process (Buckingham et al. 2009). In the case of the α7 nAChR, JAK-2 
kinase is able to bind to this nAChR subtype under nicotinic stimulation, to transduce signals 
to PI3-kinase and Akt (Shaw et al. 2002), which results in neuroprotection. Our results show 
that only stimulation of the α7 and not the β2* nAChR can induce JAK-2 phosphorylation. 
Activation of the JAK-2/PI3K/Akt route can be independent of Ca2+ (Chernyavsky et al. 
2009) which agrees with the results of this study. The implication of this kinase in protection 
mediated by α7 nAChR was confirmed when protection induced by PNU 282987, but not by 
5IA 85380, was lost in cells treated with the JAK-2 inhibitor AG-490. Furthermore, the loss 
of protection by the α7 agonist in the presence of the allosteric modulator seems to be related 
to the loss of phosphorylation of JAK-2 under similar conditions, as determined by the 
western blot experiments (Fig. 4C). 
Continuing with the intracellular signalling pathways, data from other groups 
(Buckingham et al. 2009; Quesada et al. 2008) as well as our own (Arias et al. 2005; Canas et 
al. 2007) have shown that activation of PI3K/Akt is related to cell survival. In line with these 
observations, we have seen that both PNU 282987 and 5IA 85380 increased Akt 
phosphorylation. Furthermore, the PI3K inhibitor LY 294002 blocked the protective effects of 
the α7 and β2* agonist. Therefore, this signalling pathway is shared by both nAChR subtypes. 
In the case of α7 nAChR, it has been described that one of the targets of JAK-2 is precisely 
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PI3K/Akt (Shaw et al. 2002); these kinases can be activated in a Ca2+-dependent (Soletti et 
al.) or independent manner (Chernyavsky et al. 2009). 
Based on a previous study that showed that non α7 nAChRs are able to activate 
MAPK/ERK in a Ca2+-dependent way (Nakayama et al. 2001) we evaluated if 5IA 85380 
could induce ERK 1/2 phosphorylation. In our experimental conditions, ERK1/2 activation 
was only induced by 5IA 85380. Participation of MAPK in β2* nAChR-mediated protection 
was supported with the experiments with the inhibitor PD98059 (Fig. 6C).  
Since both agonists activated Akt, we tried to identify Akt targets which could be 
related to the mechanism of action of OA, which induces τ hyperphosphorylation. One of the 
kinases that phosphorylates τ is GSK-3β (Grimes and Jope 2001), and it is known that P-Akt 
inactivates GSK-3β by phosphorylation of its Ser-9 (Cross et al. 1995; Srivastava and Pandey 
1998). We observed that α7 and β2* nAChR stimulation increased  phosphorylation of Ser-9-
GSK-3β after 15 min but it decreased after 24h exposure to the agonist. This temporal pattern 
excludes sustained inactivation of GSK-3β as a prerequisite for the observed neuroprotection. 
However, protection mediated by both nAChR subtypes does seem to be related to inhibition 
of GSK-3β since the combination of AR-A014418 (a GSK-3β inhibitor) with the α7 or β2* 
nAChR agonist did not afford additional protective effects (fig. 7G).  
After exposing the cells for 16 h to OA, total GSK-3β expression was increased by 
almost two-fold. Increases in the expression of GSK-3β have been reported in glial progenitor 
cells of Alzheimer´s disease patients treated with Aβ (He and Shen 2009) as well as in post-
mortem brain of Alzheimer patients (Lau et al. 1999). In fact, there are several transgenic 
models that over-express GSK-3β and reproduce many pathophysiological features of 
Alzheimer disease (Engel et al. 2006). Taken together, OA seems to increase the expression 
of GSK-3β as observed in Alzheimer´s disease patients. Therefore, reduction of total GSK-3β 
expression induced by nicotinic agonists and the GSK-3β inhibitor could be an interesting 
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therapeutic approach. Recent studies have shown that lithium, a GSK-3β inhibitor, and 
tobacco extracts are able to reduce mRNA and GSK-3β protein levels respectively (Mendes et 
al. 2009; Tian et al. 2009). Moreover, total Tyr-216-GSK-3β phosphorylation (active levels) 
was also increased by OA alone and this increase was significantly reduced by nAChR 
agonists and AR- A014418. 
GSK-3β specifically phosphorylates Ser-396/404 of τ (PHF-1, Paired Helicoidal 
Filament-1) both in cell cultures (Lovestone et al. 1994; Tanaka et al. 1998) and “in vivo” 
models (Spittaels et al. 2000). τ hyperphosphorylation by PP2A inhibition induces a 
disruption of microtubules causing cell death in SH-SY5Y cells treated with OA (Tanaka et 
al. 1998). This microtubule destabilisation compromises axonal transport and induces 
neurodegeneration of neurons with tangles, a widely accepted characteristic in brains of 
Alzheimer´s disease patients (Alonso et al. 1994; Alonso et al. 1997). We have observed that 
OA almost doubled τ phosphorylation on its Ser-396/404 and that the α7 and β2* nicotinic 
agonists, together with the GSK-3β inhibitor, reduced Ser-396/404-τ-hyperphosphorylation. 
Furthermore, cytoskeleton alterations caused by okadaic acid were partially reverted with 
nAChR agonist treatment (Fig. 10). 
Apart from reducing tau phosphorylation, nicotinic stimulation also confers 
neuroprotection and anti-inflammatory actions by activation of some of the intracellular 
pathways here described (Marrero and Bencherif, 2009; Kawamata and Shimohama, 2011; 
Parada et al., 2010; Egea et al., 2007), which could also be contributing to the protective 
effects observed by both α7 and β2 nAChR activation. 
In conclusion, both α7 and β2* nAChR activation can mediate protection against OA. 
α7 nAChR mediated protection involves a Ca2+-independent-JAK-2/PI3K/Akt/GSK-3β 
signalling pathway. In contrast, the Ca2+-dependent protective mechanism mediated by β2* 
nAChR relates to MEK/ERK1/2, PI3K/Akt activation and GSK-3β inactivation. However, 
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both signalling pathways converge on GSK-3β down regulation and reduction of 
phosphorylation of τ in cells exposed to okadaic acid which represents a good model of 
neuronal death related to the characteristic tau hyperphosphorylation found in Alzheimer´s 
disease patients. 
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LEGENDS TO FIGURES 
 
Figure 1. Protective effects mediated by the nicotinic agonists PNU 282987 and 5IA 
85380 and the α7 allosteric modulator PNU 120596 against okadaic acid-induced 
toxicity. Cells were pre-treated for 24 hours with increasing concentrations of the α7 nicotinic 
agonist PNU282987, the β2* nicotinic agonist 5IA 85380 or the α7 positive allosteric 
modulator PNU 120596. Thereafter, SH-SY5Y were incubated for 16 h with okadaic acid 
(OA) 30 nM and at the end of the experiment cell death was evaluated by measuring the 
release of LDH release to the extracellular medium (see top of the figure). PNU 282987 (A) 
and 5IA 85380 (B) offered protection against OA-induced toxicity, however the α7 allosteric 
modulator PNU 120596 did not (C). The data represent means ± S.E.M. of triplicates of at 
least 4 different batches of cells. * p< 0.05,**p< 0.01 with respect to OA alone.  
 
Figure 2. Intracellular Ca2+ increases mediated by the nicotinic agonists PNU 282987 
and 5IA 85380 in SH-SY5Y cells loaded with Fluo-3. (A) SH-SY5Y cells were stimulated 
with 10 µM PNU 282987 alone or in cells pre-incubated during 15 min with the α7 allosteric 
modulator PNU 120596 (10 µM); PNU 120596 was also co-incubated with various nicotinic 
antagonist such as mecamylamine (“Meca” 30 µM), α-bungarotoxin (“BGT” 100 nM) or 
methyllycaconitine (“MLA” 100 nM). (B) Cytosolic Ca2+ increases induced by 5IA 85380 at 
100 µM alone or in the presence of the nicotinic antagonist Meca 30 µM, BGT 100 nM, α-
conotoxin-AuIB (“AuIB” 10 µM), dihydro-β-eritroidine (“DHβE” 10 µM) or α-conotoxin-
MII (“MII” 200 nM). The data represent the average of maximum fluorescence increases 
during 10 seconds after the implementation of PNU 282987 10 µM (A) or 5IA 85380 100 µM 
(B). Experiments were conducted in triplicate on at least 6 different batches of cells. 
***p < 0.001 with respect to PNU 282987 alone (A) or with respect to 5IA 85380 (B); 
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###p < 0.001 with respect to PNU 282987+PNU 120596 (B); **p < 0.01 with respect to 5IA 
85380 (B).  
 
Figure 3. Time and Ca2+ dependence of cytoprotection mediated by PNU 282987 and 
5IA 85380. As shown in the upper panel, cells were incubated with PNU 282987 (10 µM) (A) 
or 5IA 85380 (100 µM) (B) during 5 min, 1 h, 4 h or 24 h, then the agonist was removed and 
fresh EMEM was added until to complete 24 h; after this period, EMEM was replaced by OA 
(30 nM) for 16 h. At the end of the experiment, cell death was evaluated by LDH. Figures (C) 
and (D) show the mean of LDH values when agonists were pre-incubated for 4 h in the 
presence or absence of extracellular Ca2+ using the same protocol described above. PNU 
120596 (“PNU 12” 10 µM) was pre-incubated for 15 min and co-incubated during the 
application of PNU 282987 (C). Data represents the mean of LDH values normalized with 
respect to OA alone ± S.E.M. of triplicates of at least 6 different cultures. *p < 0.05, 
**p < 0.01 and ***p < 0.001 with respect to OA; #p < 0.05 and ###p < 0.001 with respect to 
the agonists plus OA.  
 
Figure 4. Differential phosphorylation and implication of JAK-2 in neuroprotection 
mediated by PNU 282987 and 5IA 85380.  PNU282987 (A), 5IA 85380 (B) and PNU 
282987 plus the allosteric modulator PNU 120596 were incubated during different time 
periods (5 min, 15 min, 30 min, 1 h and 24 h); at the end, P-JAK-2 (immunoblots on the top) 
and JAK-2 total (immunoblots at the bottom) were quantified by western blot. (D) Represents 
the effect of the JAK-2 inhibitor, AG-490, on the neuroprotective action of PNU 282987 10 
µM (“PNU 28”) and 5IA 85380 100 µM (“5IA”). Data are the mean ± S.E.M. of at least 4 
different cultures; *p < 0.05 with respect to the basal (A); ***p < 0.001 with respect to OA 
alone and #p < 0.05 with respect to PNU 282987 (B).  
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Figure 5. Phosphorylation of Akt and implication of PI3K in neuroprotection mediated 
by PNU 282987 and 5IA 85380. Akt phosphorylation by PNU 282987 10 µM (A) and 5IA 
85380 100 µM (B) at different incubation periods. (C) Shows the effect of the PI3K inhibitor 
3 µM LY 294002 on the neuroprotection mediated by PNU 282987 10 µM (“PNU 28”) and 
5IA 85380 100 µM (“5IA”) against OA-induced toxicity. Each value is a mean of at least 4 
different cell cultures ± S.E.M. *p < 0.05 and **p < 0.01 with respect to the basal in figures 
(A) and (B); ***p < 0.001 with respect to OA alone, #p < 0.05 with respect to PNU 282987, 
$$p < 0.01 with respect to 5IA 85380 (C).  
 
Figure 6. Phosphorylation of ERK 1/2 and implication of MEK in neuroprotection 
mediated by PNU 282987 and 5IA 85380. ERK 1/2 phosphorylation by PNU 282987 10 µM 
(A) and 5IA 85380 100 µM (B) at different incubation periods. (C) Shows the effect of the 
MEK inhibitor PD 98059 1µM on neuroprotection mediated by PNU 282987 10 µM (“PNU 
28”) and 5IA 85380 100 µM (“5IA”) against OA-induced toxicity. Each value is a mean of at 
least 4 different cell cultures ± S.E.M. *p < 0.05 with respect to the basal in (B); ***p < 0.001 
with respect to OA alone, ##p < 0.01 with respect to 5IA 85380 (C).  
 
Figure 7. GSK-3β phosphorylation and implication in neuroprotection mediated by PNU 
282987 and 5IA 85380. Time course of Ser-9 were analysed by western blot in protein 
extracts obtained from cells treated with PNU 282987 10 µM (A) and 5IA 85380 100 µM (B) 
during different time periods. (C) Shows the effect of the GSK-3β inhibitor AR-A014418 
1µM on the neuroprotection mediated by PNU 282987 10 µM (“PNU 28”) and 5IA 85380 
100 µM (“5IA”) against OA-induced toxicity. Each value is a mean of at least 4 different 
cultures ± S.E.M. *p < 0.05 with respect to the basal in (A and B); *p < 0.05, **p < 0.01 and 
***p < 0.001 with respect to OA alone (C).    
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Figure 8. GSK-3β expression/phosphorylation under the treatment of OA. Protein 
samples were collected from cells that were pre-incubated for 24 h with PNU 282987 10 µM, 
5IA 85380 100 µM or AR-A014418 1 µM and, subsequently this pre-treatment was replaced 
by medium with OA 30 nM for 16 hours. Histograms represent the densitometric 
quantification of total GSK-3β (A) and total Tyr-216 (B) phosphorylation, using β-actin for 
normalization. Each value is a mean of 4 different cultures ± S.E.M. *p < 0.05, **p < 0.01 
with respect to basal levels and, #p < 0.05, ##p < 0.01 and ###p < 0.001 with respect to OA 
alone.  
 
Figure 9. Effect of nicotinic agonists and AR-A014418 on Ser-396/404 τ phosphorylation 
in cells treated with AO. Protein samples were collected from cells that were pre-incubated 
for 24 h with PNU 282987 10 µM, 5IA 85380 100 µM or AR-A014418 1 µM and 
subsequently medium was replaced by OA 30 nM for 16 hours. Histograms represent the 
densitometric quantification of P-Ser-396/404-τ, using τ total for normalization. Each value is 
a mean of 5 different cultures ± S.E.M. ***p < 0.001 with respect to basal levels and 
#p < 0.05 with respect to OA alone.  
 
 
Figure 10. PNU 282987 and 5IA 85380 partially prevent cytoarchitecture disruption 
elicited by OA. Photomicrographs of double staining of SH-SY5Y marked with Rhodamine-
phalloidin (filamentous actin marker, red) and Hoechst (nuclear marker, blue). Cells were 
incubated with PNU 282987 (10 µM) (C) or 5IA 85380 (100 µM) (D) during 24 h, then OA 
30 nM was added for 5h. A control group without any treatment (A) and another just treated 
with OA 30 nM for 5 h were run in parallel (B). As shown in the photomicrographs, PNU 
282987 and 5IA 85380 prevented partially the cytoarchitecture alterations caused by OA. 
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